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Abstract
The effects of progesterone and 17L-estradiol on Ca2 signaling in in situ endothelial cells were investigated using front-
surface fluorometry of fura-2-loaded strips of porcine aortic valve. Progesterone inhibited the thapsigargin-induced sustained
[Ca2]i elevation (IC50 = 33.9 WM, n = 4), while 17L-estradiol added a transient [Ca2]i elevation. Progesterone and 17L-
estradiol had no significant effect on the thapsigargin-induced [Ca2]i elevations in the absence of extracellular Ca2. A
Mn2-induced decline of fluorescent intensity at 360 nm excitation was accelerated by thapsigargin. This acceleration was
completely reversed by progesterone, but not by 17L-estradiol. Progesterone inhibited, and 17L-estradiol enhanced the
endothelin-1 (ET-1)-induced [Ca2]i elevation, while both had no effect on the ET-1-induced Ca2 release observed in the
absence of extracellular Ca2 or in the pertussis toxin-treated strips. Progesterone and 17L-estradiol thus had different effects
on Ca2 signaling, especially on Ca2 influx, in endothelial cells. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The incidence of cardiovascular diseases in preme-
nopausal women is lower than that observed with
postmenopausal women or age-matched men [1].
Hormone replacement therapy in postmenopausal
women is associated with an approx. 50% reduction
in the incidence of coronary events [2]. These obser-
vations led us to the hypothesis that estrogen may
play a protective role in the development of cardio-
vascular disease [3]. The mechanisms of the cardio-
protective e¡ects of estrogen could be multifactorial.
It was reported that estrogen increases HDL choles-
terol and reduces LDL cholesterol, thereby reducing
the risk of cardiovascular disease [4]. Furthermore,
estrogen has been shown recently to act directly on
the cardiovascular system and thereby modulate vas-
cular tone [5]. Estrogen has been reported to relax
arterial tissue both with and without endothelium
[6,7]. Recently, a number of studies revealed that
estrogen increased the expression of nitric oxide
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synthase, enhanced nitric oxide production and aug-
mented endothelium-dependent vasorelaxation [6].
Although progesterone is included in most hormone
replacement therapy regimens to reduce the risk of
developing uterine cancer, less is known about the
e¡ect of progesterone on the cardiovascular system.
There are several studies demonstrating that proges-
terone induced relaxations in the vascular, uterine,
airway, urinary tract and intestinal smooth muscles
[8^12]. However, the e¡ect of progesterone on the
endothelial function has not yet been examined.
The e¡ect of progesterone on the improvement of
the endothelial function by estrogen in combined
hormone replacement therapy still remains contro-
versial. Some groups have reported that progesterone
attenuated the estrogen-induced enhancement of en-
dothelium-dependent relaxation in animal studies
[13] and the improvement of endothelium-dependent
vasodilation in hormone replacement therapy [14].
Others did not observe such antagonizing e¡ect of
progesterone on the endothelial function [15,16].
The vascular endothelium plays an important role
in the regulation of vascular tone by producing both
relaxing and contracting factors. Cytosolic Ca2 con-
centration ([Ca2]i) is an important determinant of
the production of these factors [17,18]. We previously
reported that endothelin-1 induced a transient in-
crease in [Ca2]i due to both Ca2 release and in£ux
in in situ endothelial cells of porcine aortic valve [19],
and that cyclopiazonic acid, an inhibitor of the Ca2
pump of endoplasmic reticulum, caused a large in-
crease in [Ca2]i mainly due to Ca2 in£ux [20].
These increases in [Ca2]i were associated with endo-
thelium-dependent relaxation [19,20]. In spite of the
important role of [Ca2]i in regulating vascular tone,
there has been no report regarding the e¡ects of es-
trogen and progesterone on the regulation of [Ca2]i
in endothelial cells.
In the present study, we investigated the e¡ects
of progesterone and 17L-estradiol on Ca2 signaling
in in situ endothelial cells. Front-surface £uorometry
of fura-2-loaded strips of porcine aortic valve [21]
was performed to examine their e¡ects on [Ca2]i
increases induced by thapsigargin and receptor-
mediated stimulations including ET-1, bradykinin
and substance P. A Mn2 quenching technique was
also utilized to directly evaluate the e¡ects on Ca2
in£ux.
2. Materials and methods
2.1. Preparation of strips from porcine aortic valves
Strips of porcine aortic valve were prepared as
previously described [22]. Aortic roots with an intact
aortic valve were obtained from adult pigs of either
sex at a local slaughterhouse immediately after the
animals had been killed, and brought back to the
laboratory in ice-cold normal physiological salt solu-
tion (PSS). The aortic valve lea£ets were cut into
strips in an axial direction. The size of the strip
was approx. 3 mm wide, 5 mm long, and 0.18 mm
thick. The cells on the aortic side were active in up-
take of acetylated low density lipoprotein labeled
with 1,1P-dioctadecyl-3,3,3P,3P-tetramethylindocarbo-
cyanine perchlorate (DiI-Ac-LDL), and expressed
endothelial constitutive nitric oxide synthase, as evi-
denced by a reverse transcription-polymerase chain
reaction analysis (data not shown).
2.2. Fura-2 loading in endothelial cells of the valvular
strips
The valvular strips were incubated for 90 min at
37‡C in Dulbecco’s modi¢ed Eagle’s medium, gassed
with a mixture of 95% O2 and 5% CO2, containing
25 WM fura-2/AM (an acetoxymethyl ester form of
fura-2), 1 mM probenecid and 5% fetal bovine se-
rum. Probenecid was added to prevent an extrusion
of fura-2 [23]. After loading with fura-2, the strips
were washed with normal PSS and equilibrated for
60 min at room temperature before starting the mea-
surements. When the strips were pretreated with per-
tussis toxin, they were incubated in normal PSS con-
taining 300 ng/ml pertussis toxin for 3 h at 37‡C, and
then loaded with fura-2 for £uorometry.
2.3. Front-surface fura-2 £uorometry of endothelial
cells in situ
Front-surface £uorometry of aortic valvular strips
was performed as previously described [21,22]. Fura-
2-loaded strips were vertically mounted in a quartz
organ bath ¢lled with the normal PSS. Strips were
illuminated with alternating (400 Hz) 340 nm and
380 nm excitation lights, and changes in the inten-
sities of 500 nm £uorescence and their ratio were
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monitored with a £uorometer CAM-OF3 (Jasco, To-
kyo, Japan). All measurements were performed at
25‡C to prevent an extrusion of the £uorescent dye
[24]. The £uorescent ratio data were expressed as a
percentage, assigning the valves at rest and at the
peak response to 10 WM ATP to be 0% and 100%,
respectively. In the experiment to assess the e¡ects of
steroid hormones on the sustained [Ca2]i elevation
induced by thapsigargin in the presence of the extra-
cellular Ca2, the level of £uorescent ratio obtained
at 30 min after the application of thapsigargin and
just before the addition of steroid hormone was as-
signed to be 100%.
2.4. Mn2+ quenching protocol
To examine the e¡ect of progesterone on the Ca2
in£ux, the Mn2 quenching protocol was utilized
[25,26]. The decline in £uorescence intensity at the
isosbestic wavelength (360 nm) excitation (F360) was
monitored as the index of Mn2 in£ux (Mn2
quenching). After exposing the strips to Ca2-free
PSS, experiments were initiated by adding 0.3 mM
Mn2, which induced a gradual decline of F360 (basal
decline). The decline of F360 during stimulation with
1 WM thapsigargin was examined in the absence and
presence of 100 WM progesterone and 17L-estradiol.
Progesterone and 17L-estradiol were added 20 min
before, and thapsigargin 10 min before the addition
of Mn2. After 20 min recording of the Mn2
quenching, strips were exposed to 25 WM ionomycin
in the presence of Mn2 to obtain a minimal level of
F360, which was determined to be comparable to the
auto£uorescence level (data not shown). The £uores-
cence intensity was expressed as a percentage, while
assigning the F360 obtained just before the addition
of Mn2 and that obtained after exposure to iono-
mycin to be 100% and 0%, respectively. The F360
decline during the initial 10 min period was then
¢tted to the exponential decline curve according to
the following formula:
F  F0e3t=d
where F0 is the F360 value at the beginning of
Mn2 quenching, t is time in min and d is a time
constant indicating the time required for F360 to de-
cline by 1/e.
2.5. Drugs and solutions
The composition of normal PSS was as follows
(mM): NaCl 123, KCl 4.7, NaHCO3 15.5, KH2PO4
1.2, MgCl2 1.2, CaCl2 1.25 and D-glucose 11.5. PSS
was bubbled with a mixture of 95% O2 and 5% CO2.
Fura-2/AM was purchased from Dojindo (Kumamo-
to, Japan), and dissolved in dimethyl sulfoxide
(DMSO) as a stock solution and then diluted in
the medium just before loading the dye. The ¢nal
concentration of DMSO was 5% in the loading me-
dium. Progesterone, 17L-estradiol and thapsigargin
were purchased from Sigma (St. Louis, MO, USA),
and dissolved in DMSO as a stock solution and di-
luted in distilled water just before use, with the ¢nal
concentration of DMSO being 9 0.1%. Ionomycin
was purchased from Sigma and dissolved in distilled
water. Endothelin-1, bradykinin and substance P
were obtained from the Peptide Institute (Osaka, Ja-
pan) and dissolved in distilled water. Pertussis toxin
was purchased from List Biological Laboratories
(CA, USA) and dissolved in distilled water.
2.6. Data analysis
The concentration to induce half the maximal ef-
fect (IC50) was calculated using the four-parameter
logistic equation [27]. The values were expressed as
the mean þ standard error of the mean (S.E.M.). One
strip obtained from one animal was used for each
experiment, therefore the number of experiments (n
value) indicates the number of animals. Student’s t-
test was used to determine statistical signi¢cance. A
P value of less than 0.05 was considered to have
statistical signi¢cance. All data were collected using
a computerized data acquisition system (MacLab,
Analog Digital Instruments, Castle Hill, Australia;
Macintosh, Apple Computer, USA).
3. Results
3.1. E¡ect of progesterone and 17L-estradiol on
thapsigargin-induced [Ca2+]i elevation in the
presence of extracellular Ca2+
In the presence of extracellular Ca2, thapsigargin,
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a Ca2-ATPase inhibitor, induced a biphasic eleva-
tion of [Ca2]i, composed of a large transient eleva-
tion reaching the peak level by 10 min, and a sub-
sequent sustained elevation that was attained 20 min
after the peak (Fig. 1A). The level of the sustained
[Ca2]i elevation was maintained for more than 60
min. The level of the peak [Ca2]i elevation was
649.7 þ 80.0% (n = 6) of the peak level of 10 WM
ATP-induced [Ca2]i elevation, and the level of
[Ca2]i at 30 min and 90 min after stimulation by
thapsigargin was 482.2 þ 68.4%, 439.1 þ 51.6%
(n = 6), respectively. As a result, no signi¢cant de-
crease was seen in [Ca2]i (Ps 0.05) during the sus-
tained phase of the thapsigargin-induced [Ca2]i ele-
vation. When DMSO was added 30 min after the
application of thapsigargin, the level of [Ca2]i at
60 min after the application of DMSO (90 min after
the application of thapsigargin) was 453.3 þ 40.9%
(n = 6). There was no signi¢cant di¡erence in
[Ca2]i seen at 90 min after stimulation with thapsi-
gargin between the presence and absence of DMSO,
thus suggesting that 0.1% DMSO had no signi¢cant
e¡ect on the thapsigargin-induced [Ca2]i elevation.
Fig. 1B and C show representative recordings of
the e¡ects of 100 WM progesterone and 100 WM 17L-
estradiol on the sustained [Ca2]i elevation induced
by 1 WM thapsigargin. When progesterone was added
during the sustained phase of the thapsigargin-in-
duced [Ca2]i elevation, [Ca2]i gradually decreased
to 24.3 þ 2.1% (n = 6) at 60 min, while assuming the
[Ca2]i level obtained with 1 WM thapsigargin to be
Fig. 2. Concentration-dependent e¡ects of progesterone and
17L-estradiol on thapsigargin-induced [Ca2]i elevation. The lev-
el of [Ca2]i at 60 min after the application of progesterone
and 0.1% dimethyl sulfoxide are shown. The e¡ect of 17L-estra-
diol was evaluated at two time points: at the peak of initial
transient elevation of [Ca2]i, and at 60 min after the applica-
tion. The [Ca2]i levels are expressed as a percentage, assigning
the levels at rest and just before the application of 0.1% di-
methyl sulfoxide or steroid hormones to be 0 and 100%, respec-
tively. We obtained the concentration-response curves for the
e¡ects of estrogen and progesterone by applying each steroid
hormone at each concentration to each valvular strip. The data
are the mean þ S.E.M. (n = 6). *Signi¢cantly di¡erent from the
control levels obtained with 0.1% DMSO (vehicle) alone
(P6 0.05). 2Signi¢cantly di¡erent from the levels obtained at
the peak of initial transient elevation of [Ca2]i induced by
17L-estradiol.
Fig. 1. E¡ects of progesterone and 17L-estradiol on the thapsi-
gargin-induced [Ca2]i elevation in the presence of extracellular
Ca2. Representative recordings of the changes in [Ca2]i in-
duced by 10 WM ATP and 1 WM thapsigargin in the presence
of extracellular Ca2. The vehicle (0.1% dimethyl sulfoxide)
(A), 100 WM progesterone (B) and 100 WM 17L-estradiol (C)
were applied 30 min after the stimulation by thapsigargin. The
addition of vehicle had no e¡ect on the thapsigargin-induced
[Ca2]i elevation, while progesterone decreased it, and 17L-es-
tradiol induced a transient further increase in [Ca2]i.
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100% (Fig. 1B). On the other hand, when 17L-estra-
diol was added during the sustained phase of the
thapsigargin-induced [Ca2]i elevation, it induced
an additional transient increase in [Ca2]i reaching
a peak at 5 min, but did not induce an apparent
decrease in sustained elevation of [Ca2]i (Fig. 1C).
We determined the concentration-response curves for
the e¡ects of estrogen and progesterone by applying
the steroid hormones at various concentrations to
the valvular strips. When evaluated at 60 min after
the application of progesterone, the e¡ect of proges-
terone was concentration-dependent, with an IC50
value of 36.8 WM (n = 6) (Fig. 2). The maximal in-
hibitory e¡ects was obtained at 100 WM. The concen-
tration-dependent e¡ects of 17L-estradiol on the
thapsigargin-induced [Ca2]i elevation were thus
evaluated at two time points: at the peak of the
initial transient [Ca2]i elevation and at 60 min after
the addition of 17L-estradiol (Fig. 2). A transient
elevation of [Ca2]i was observed at 10 WM and high-
er concentrations of 17L-estradiol. The maximum
level of [Ca2]i elevation (117.0 þ 1.6%, n = 6) was
obtained at 100 WM. On the other hand, when eval-
uated at 60 min after application, 17L-estradiol, even
at 100 WM, did not signi¢cantly change the sustained
phase of the thapsigargin-induced [Ca2]i elevation
compared to the control [Ca2]i level obtained in
the absence of 17L-estradiol (Ps 0.05).
3.2. E¡ects of progesterone and 17L-estradiol on
thapsigargin-induced Ca2+ release
To examine the e¡ects of progesterone and 17L-
estradiol on the Ca2 release component of thapsi-
gargin-induced [Ca2]i increase, the change in [Ca2]i
induced by 1 WM thapsigargin was evaluated in the
absence of extracellular Ca2. When the valvular
strips were exposed to Ca2-free PSS containing
2 mM EGTA, [Ca2]i gradually declined to reach a
new steady level within 5 min. Subsequently, 1 WM
thapsigargin caused a transient [Ca2]i elevation until
reaching a peak at 5 min, followed by a rapid de-
crease to a prestimulation level within 20 min (Fig.
3A). Since no sustained [Ca2]i elevation was ob-
served in the Ca2-free medium, the sustained
[Ca2]i elevation observed in the presence of the
extracellular Ca2 was considered to be due to the
in£ux of the extracellular Ca2. As shown in Fig.
3B,C, pretreatment with 60 WM progesterone or
17L-estradiol 5 min before the exposure to the
Ca2-free medium had no e¡ect on the gradual de-
cline of the resting [Ca2]i level and the subsequent
thapsigargin-induced transient [Ca2]i elevation. The
levels of [Ca2]i just before (357.2 þ 5.5%, n = 5) and
at the peak (24.1 þ 11.3%, n = 5) of the thapsigargin-
induced [Ca2]i elevation obtained in the presence of
60 WM progesterone were not signi¢cantly di¡erent
from those obtained in its absence (360.7 þ 5.5%,
31.7 þ 16.3%, n = 5) (data not shown). Pretreatment
with 17L-estradiol had no e¡ect on the level of
[Ca2]i just before (342.4 þ 5.6%, n = 5) and at the
peak (36.4 þ 8.0%, n = 5) of the thapsigargin-induced
[Ca2]i elevation, when compared with those ob-
tained in the absence of 17L-estradiol (356.4 þ
10.6%, 29.4 þ 17.1%, n = 5) (data not shown).
Fig. 3. E¡ects of progesterone and 17L-estradiol on the Ca2
release induced by thapsigargin. Representative recordings of
the change in [Ca2]i induced by 1 WM thapsigargin in the
Ca2-free medium containing 2 mM EGTA, in the strips un-
treated (A) and pretreated with 60 WM progesterone (B) and 60
WM 17L-estradiol (C). Steroid hormones were added 5 min be-
fore exposure to the Ca2-free solution. In all cases, thapsigar-
gin induced a similar transient elevation of [Ca2]i.
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3.3. E¡ect of progesterone and 17L-estradiol on Ca2+
in£ux
To investigate the mechanism underlying the in-
hibitory e¡ects of progesterone on the thapsigargin-
induced sustained [Ca2]i elevation, the Mn2
quenching protocol was utilized to directly assess
the e¡ects on the Ca2 in£ux. Fig. 4 shows represen-
tative recordings of the Mn2-induced decline of
£uorescent intensity at 360 nm excitation (F360) in
the absence of extracellular Ca2. Fig. 5 summarizes
the results of six independent experiments. The ap-
plication of 0.3 mM Mn2 caused a gradual decline
of F360 (the basal decline, trace a). The level of F360
decreased to 53.3 þ 3.1% (n = 6) at 20 min (Fig. 5),
assigning the levels of F360 before the addition of
MnCl2 and after the addition of ionomycin to be
0% and 100%, respectively. In the presence of 1 WM
thapsigargin, the Mn2-induced decline of F360 was
accelerated (Fig. 4, trace b), and the level of F360 at
20 min was 34.5 þ 5.6% (n = 6). This value was sig-
ni¢cantly lower than that obtained with the basal
decline (P6 0.05). When the strips were treated
with 100 WM progesterone, the thapsigargin-induced
acceleration was completely reversed (Fig. 4, trace c).
The level of F360 at 20 min after the application of
Mn2 in the presence of progesterone and thapsigar-
gin was 63.0 þ 2.6% (n = 6) (Fig. 5). This value did
not signi¢cantly di¡er from that obtained with the
basal decline. On the other hand, the pretreatment
with 100 WM 17L-estradiol had no e¡ect on the thap-
sigargin-induced acceleration of the F360 decline (Fig.
4, trace d). The level of F360 at 20 min after the
addition of Mn2 in the presence of 17L-estradiol
and thapsigargin was 36.6 þ 3.2% (n = 6) (Fig. 5).
This level did not signi¢cantly di¡er from that ob-
tained in the presence of thapsigargin.
The decline of F360 during the initial 10 min was
¢tted to an exponential curve, and a time constant
was determined as described in Section 2 (Table 1).
Thapsigargin signi¢cantly decreased the time con-
stant obtained for the basal decline (37.7 þ 5.3,
n = 6) to 18.5 þ 4.2 (n = 6). The time constant for
the decline obtained in the presence of thapsigargin
Fig. 5. Summary of the e¡ects of progesterone and 17L-estra-
diol on Mn2 in£ux accelerated by thapsigargin. The level of
F360 was expressed as a percentage, assigning the values ob-
tained just before the addition of Mn2 and after exposure to
25 WM ionomycin to be 100% and 0%, respectively. The data
are the mean þ S.E.M. (n = 6).
Fig. 4. E¡ects of progesterone and 17L-estradiol on Mn2 in-
£ux accelerated by thapsigargin. The superimposed presentation
of the representative recordings of the decline of fura-2 £uores-
cence at 360 nm excitation (F360) induced by 0.3 mM Mn2 in
the absence of extracellular Ca2. Progesterone and 17L-estra-
diol (100 WM) were added 20 min before and thapsigargin (1
WM) 10 min before the addition of Mn2. The Mn2-induced
decline of £uorescent intensity at 360 nm excitation (F360) was
accelerated by thapsigargin. This thapsigargin-induced accelera-
tion was completely reversed by progesterone; however, 17L-es-
tradiol had no e¡ect on Mn2 in£ux.
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and progesterone was signi¢cantly greater than that
obtained with thapsigargin in the absence of proges-
terone (P6 0.05). This value did not signi¢cantly
di¡er from that obtained for the basal decline
(Ps 0.05). On the other hand, 100 WM 17L-estradiol
had no signi¢cant e¡ect on the time constant of F360
decline obtained with thapsigargin.
Since the application of 17L-estradiol caused a
transient elevation of [Ca2]i during the sustained
phase of the thapsigargin-induced [Ca2]i elevation
(Fig. 1C), the e¡ect of 17L-estradiol on the Mn2-
induced F360 decline was also examined by adding
17L-estradiol at 5 min and 10 min after the decline
was initiated by Mn2 in the presence of thapsigar-
gin. No apparent acceleration or retardation of the
F360 decline was observed after the application of 100
WM 17L-estradiol (data not shown).
3.4. E¡ect of progesterone and 17L-estradiol on the
[Ca2+]i increases induced by receptor-mediated
stimulations
Fig. 6 shows the e¡ects of 60 WM progesterone and
60 WM 17L-estradiol on the [Ca2]i elevations in-
duced by 100 nM ET-1 and 100 nM bradykinin in
the presence of extracellular Ca2. After recording
the [Ca2]i response to 10 WM ATP in normal PSS,
either ET-1 or bradykinin was applied. ET-1 caused
an initial rapid elevation of [Ca2]i reaching a peak
level (332.1 þ 28.3%, n = 6) at 1.5 min, and then pro-
gressively declined to 19.1 þ 9.5% (n = 6) at 20 min.
When the strips were pretreated with 60 WM proges-
terone 10 min before the stimulation by ET-1, the
[Ca2]i levels at the peak and at 20 min were
236.7 þ 27.8% and 18.8 þ 3.5% (n = 6), respectively.
The peak level was signi¢cantly inhibited by proges-
terone (P6 0.05), while the level at 20 min obtained
in the presence of progesterone did not signi¢cantly
di¡er from that obtained in its absence. On the other
hand, when pretreated with 17L-estradiol, the level of
[Ca2]i elevation induced by ET-1 was 449.0 þ 45.6%
at the peak and 30.2 þ 29.3% (n = 6) at 20 min. The
peak level was signi¢cantly increased (P6 0.05) while
17L-estradiol had no e¡ect on the [Ca2]i level seen
at 20 min. Bradykinin also caused a rapid elevation
of [Ca2]i reaching a peak level (280.1 þ 32.9%, n = 6)
at 1.0 min, and then declined to 13.7 þ 6.9% (n = 6) at
20 min (Fig. 6B). The bradykinin-induced [Ca2]i
elevation observed in the presence of 60 WM proges-
terone (271.7 þ 47.7% at the peak, 10.1 þ 7.2% at 20
min, n = 6) or 60 WM 17L-estradiol (289.3 þ 44.3% at
the peak, 12.6 þ 7.9% at 20 min, n = 6) did not sig-
ni¢cantly di¡er from that observed in their absence.
Substance P also induced a similar transient [Ca2]i
elevation to that seen with bradykinin. Progesterone
and 17L-estradiol had no e¡ect on the substance P-
induced [Ca2]i elevation (data not shown).
To investigate the e¡ects of progesterone and 17L-
estradiol on the Ca2 release component of ET-1-
induced [Ca2]i increase, the change in [Ca2]i in-
duced by 100 nM ET-1 was evaluated in the absence
of extracellular Ca2. After a 5 min exposure to
Ca2-free PSS containing 2 mM EGTA, the applica-
tion of ET-1 caused a transient [Ca2]i elevation
reaching a peak at 1.5 min. The level of [Ca2]i
just before and at the peak of the ET-1-induced
[Ca2]i elevation were 342.7 þ 4.8% (n = 6) and
165.9 þ 29.1% (n = 6) (Fig. 6C). Those values ob-
tained in the presence of progesterone (332.9 þ
4.9% and 109.1 þ 24.5%, n = 6), and 17L-estradiol
(345.8 þ 9.4% and 142.3 þ 19.1%, n = 6) did not di¡er
from the control values (Fig. 6C).
When the strips were treated with 300 ng/ml per-
tussis toxin for 3 h at 37‡C, and were loaded with
fura-2 thereafter, ET-1 caused a smaller elevation of
[Ca2]i with the peak elevation to 140.4 þ 9.0%
(n = 4). This level was similar to that obtained in
the absence of extracellular Ca2. In the pertussis
toxin-treated strips, treatment with 60 WM progester-
one and 60 WM 17L-estradiol 10 min before stimula-
tion with ET-1 had no e¡ect on the subsequent
Table 1
Time constant of F360 decline in Mn2 quenching
3thapsigargin +thapsigargin
Control 37.7 þ 5.3 18.5 þ 4.2
+100 WM progesterone n.d. 40.2 þ 2.6
+100 WM 17L-estradiol n.d. 20.1 þ 1.9
The F360 decline during the initial 10 min period in the Mn2
quenching protocol (Fig. 5) was ¢tted to the exponential decline
curve, and the time constant was determined as described in
Section 2. The basal decline was induced by 0.3 mM MnCl2 in
the absence of thapsigargin (3thapsigargin). The e¡ect of 100
WM progesterone and 100 WM 17L-estradiol on the 1 WM thap-
sigargin-induced acceleration of F360 decline (+thapsigargin) was
examined. Data are the mean þ S.E.M. (n = 6). n.d., not deter-
mined.
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[Ca2]i elevation induced by ET-1. The peak levels of
[Ca2]i obtained with progesterone and 17L-estradiol
were 146.8 þ 20.4% and 135.7 þ 12.9% (n = 3), respec-
tively. These values did not signi¢cantly di¡er from
those obtained in the absence of steroid hormones.
4. Discussion
The major ¢nding of the present study is that pro-
gesterone inhibited the [Ca2]i elevations induced by
thapsigargin and ET-1 in in situ endothelial cells of
Fig. 6. E¡ects of progesterone and 17L-estradiol on agonist-induced [Ca2]i elevations. (A,B) E¡ects of 60 WM progesterone and 60
WM 17L-estradiol on the time courses of change in [Ca2]i induced by 100 nM ET-1 (A) and 100 nM bradykinin (B). Progesterone
and 17L-estradiol were applied 10 min prior to the application of ET-1 or bradykinin. The resting level and peak response to 10 WM
ATP were assigned to be 0% and 100%, respectively. The data are the mean þ S.E.M. (n = 6). *Signi¢cantly di¡erent from the corre-
sponding control levels (P6 0.05). (C) E¡ects of progesterone and 17L-estradiol on the ET-1-induced [Ca2]i increase in the absence
of extracellular Ca2. The bottom and the top of each column represent the levels of [Ca2]i just before and at the peak obtained by
the application of ET-1, respectively, and in the absence (control) and presence of 60 WM progesterone and 60 WM 17L-estradiol. The
resting level and peak response to 10 WM ATP were assigned to be 0% and 100%, respectively. The data are the mean þ S.E.M.
(n = 6). N.S., not signi¢cantly di¡erent.
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the porcine aortic valve, and that this inhibitory ef-
fect is mainly due to the inhibition of Ca2 in£ux
with no e¡ect on Ca2 release. This is the ¢rst report
describing the inhibitory e¡ect of progesterone on
the Ca2 in£ux in endothelial cells. The speci¢city
of the inhibitory e¡ect on the Ca2 in£ux was sup-
ported by the following observations. (1) Progester-
one inhibited the extracellular Ca2-dependent in-
creases in [Ca2]i. (2) Progesterone inhibited the
Mn2 in£ux accelerated by thapsigargin. (3) Proges-
terone had no e¡ect on the [Ca2]i elevations induced
by thapsigargin or ET-1 in the absence of extracellu-
lar Ca2. Such an elevation was considered to be due
to Ca2 release from the intracellular store sites. (4)
Progesterone had no e¡ect on the [Ca2]i elevation
induced by ET-1 in the pertussis toxin-treated endo-
thelial cells. We previously reported that pertussis
toxin speci¢cally inhibited the Ca2 in£ux induced
by ET-1 in the porcine aortic valve [22]. The
[Ca2]i elevation observed in the pertussis toxin-
treated strips was thus considered to be mainly due
to Ca2 release. Furthermore, the observations that
progesterone had no e¡ect on the [Ca2]i elevations
induced by bradykinin and substance P may also add
supportive evidence to the speci¢city of the inhibi-
tory e¡ect on the Ca2 in£ux. Since the bradykinin-
induced [Ca2]i elevations in the presence of external
Ca2 did not di¡er from those observed in the
absence of external Ca2, the bradykinin-induced
[Ca2]i elevation was suggested to be mainly due to
Ca2 release [22].
In addition to the inhibitory e¡ect of progesterone
on the Ca2 in£ux, and more importantly, we found
di¡erences in the e¡ects on Ca2 signaling in endo-
thelial cells between estrogen and progesterone. 17L-
Estradiol did not have any inhibitory e¡ect but
rather an enhancing e¡ect on the [Ca2]i elevations
induced by thapsigargin and ET-1. As a result, we
propose that progesterone and estrogen have oppos-
ing e¡ects on the Ca2 in£ux pathway in endothelial
cells. Although they are both ovarian steroid hor-
mones, a subtle di¡erence in chemical structure be-
tween progesterone and estrogen may contribute to
the di¡erential e¡ects on Ca2 signaling in endothe-
lial cells.
The inhibition of Ca2 in£ux by progesterone was
observed in other types of cells. In vascular smooth
muscle, progesterone was shown to induce relaxation
during contractions induced by high external K de-
polarization [8], thus suggesting that progesterone
inhibited the voltage-operated Ca2 channels. The
inhibition of the voltage-operated Ca2 channels by
progesterone was further demonstrated with a patch
clamp study in human intestinal smooth muscle cells
[28]. However, a patch clamp study with rat thoracic
aorta did not show any signi¢cant inhibition of the
voltage-operated Ca2 channels by progesterone [29].
Progesterone was also reported to inhibit the con-
tractions induced by the receptor-mediated stimula-
tions such as prostaglandin F2K [8], phenylephrine
[30] and serotonin [31] as well as K depolariza-
tion-induced contractions. Furthermore, in the rat
aorta, progesterone inhibited the norepinephrine-in-
duced contraction, which was considered to be due
to Ca2 in£ux through other entry pathways than
the voltage-operated Ca2 channels [32]. Perusquia
et al. reported that progesterone and androgens
may reduce intracellular calcium by blocking the cal-
cium in£ux both through voltage-operated Ca2
channels and receptor-mediated Ca2 channels [33].
These ¢ndings suggested that progesterone inhibits
not only voltage-operated Ca2 channels but also
other Ca2 channels. This is consistent with the ¢nd-
ing of the present study. Most endothelial cells are
known to lack voltage-operated Ca2 channels [34],
and the Ca2 in£ux of endothelial cells is mediated
by other Ca2 entry pathways. The capacitative Ca2
entry [35] is one of the Ca2 in£ux pathways oper-
able in endothelial cells, especially when cells were
stimulated by thapsigargin. In T lymphocyte, which
also lacks voltage-operated Ca2 channels [36], pro-
gesterone was shown to inhibit the Ca2 in£ux in-
duced by the activation of T cell receptor with no
e¡ect on the Ca2 release [37]. Collectively, we sug-
gest that progesterone may thus act as a wide-spec-
tral inhibitor of the Ca2 in£ux pathways including
the voltage-operated Ca2 channels and other types
of Ca2 in£ux pathways such as capacitative Ca2
entry.
On the other hand, the inhibition of the voltage-
operated Ca2 channel by estrogen was demon-
strated more clearly than in the case with progester-
one. The patch clamp study showed the inhibition of
the voltage-operated Ca2 channels by estrogen in
many types of cells, including both vascular and ute-
rine smooth muscle cells [29,38,39]. Estrogen was
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shown to relax contractions induced by both K
depolarization and U46619 in the porcine coronary
artery, with a more potent relaxing e¡ect on the de-
polarization-induced contractions [7]. Furthermore,
estrogen induced relaxation with no alteration of
the [Ca2]i-force relationship [7], thus suggesting
that the mechanism of estrogen-induced relaxation
is analogous to that of such Ca2 channel blockers
as diltiazem [40]. However, in the present study with
in situ endothelial cells, 17L-estradiol did not inhibit
the Ca2 in£ux induced by either thapsigargin or ET-
1. Rather, 17L-estradiol augmented the [Ca2]i eleva-
tions. Taking into account the inhibitory e¡ect on
the voltage-operated Ca2 in£ux in smooth muscle
cells, as mentioned above, we suggest that estrogen,
in contrast to progesterone, is thus a more speci¢c
inhibitor of the voltage-operated Ca2 channels.
The augmentation by 17L-estradiol of the [Ca2]i
elevations induced by thapsigargin and ET-1 was
only observed in the presence of external Ca2.
17L-Estradiol did not augment the [Ca2]i elevations
due to Ca2 release. As a result, the augmentation of
the [Ca2]i elevations may be due to the augmenta-
tion of Ca2 in£ux. However, we could not observe
an augmentation of the thapsigargin-induced Mn2
in£ux by 17L-estradiol addition either before or after
the initiation of Mn2 quenching. This may be due
to the transient nature of such an augmentation. As
clearly shown in Fig. 1, 17L-estradiol caused only a
transient increase in [Ca2]i. In the case with ET-1-
induced [Ca2]i elevation, a signi¢cant augmentation
was also observed transiently during the time course
of the [Ca2]i elevation (Fig. 6). In addition to the
inhibitory e¡ect on the Ca2 channels, estrogen was
shown to activate the voltage-activated K channels
via cGMP-dependent phosphorylation in porcine
coronary artery [41]. In endothelial cells lacking the
voltage-operated Ca2 channels, K channel openers
such as pinacidil and cromakalim increased the bra-
dykinin-induced [Ca2]i elevation in endothelial cells
[42], and hyperpolarization of the membrane poten-
tial was thus suggested to augment the electrical driv-
ing force on Ca2 and increase Ca2 entry into en-
dothelial cells [43]. It is thus possible that the
activation of K channels in endothelial cells by es-
trogen could enhance the Ca2 in£ux and thereby
increase [Ca2]i elevations induced by thapsigargin
and ET-1. Whether or not 17L-estradiol activates
K channels in endothelial cells remains to be exam-
ined.
In premenopausal women, the plasma concentra-
tions of estradiol and progesterone are approx. 0.2
nM and 2.5 nM in the early follicular phase, and 1.0
nM and 60 nM in ovulatory surge, respectively [44].
In postmenopausal women receiving hormone re-
placement therapy, the concentrations of estradiol
and progesterone reach no more than the levels
seen in the early follicular phase of premenopausal
women [15]. In the present study, the concentrations
of progesterone and 17L-estradiol required to cause a
signi¢cant e¡ect on the [Ca2]i elevations were much
higher than the physiological and therapeutic con-
centrations. In many of the experimental studies, ef-
fective concentrations of progesterone and estrogen
were in the micromolar range as observed in the
present study. An enhancement of endothelium-de-
pendent relaxations by estrogen or a smooth muscle
relaxation by estrogen and progesterone was ob-
served at 10^60 WM [7,37,45]. In spite of a much
lower plasma concentration, estrogen in hormone re-
placement therapy was shown to exert a cardiovas-
cular e¡ect and to also improve endothelium-depen-
dent relaxation [46]. The tissue concentration of 17L-
estradiol was reported to be 20 WM in placenta [47].
It is thus possible that steroid hormones may accu-
mulate in the vascular tissues due to their high lipo-
philicity and that the tissue concentrations could
reach high above the plasma levels and thus ap-
proach e¡ective concentrations as observed in exper-
imental conditions.
Steroid hormones are considered to exert not only
genomic but also non-genomic e¡ects [45]. Genomic
e¡ects are mediated by cytosolic receptors. Cytosolic
receptors of steroid hormones have high a⁄nity to-
wards ligands with Kd values being about 1 nM [48].
Therefore, the concentrations in the physiological
and therapeutic conditions can reach levels high
enough to bind to the cytosolic receptors and to in-
duce genomic e¡ects [49]. In the present study, the
e¡ective concentrations were much higher than the
physiological levels, suggesting that the e¡ects of
progesterone and 17L-estradiol on the Ca2 signaling
in endothelial cells may not be mediated by cytosolic
receptors, but rather by non-genomic e¡ects. This
was also supported by the fact that the modulation
of [Ca2]i in endothelial cells took place in the order
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of minutes. The genomic e¡ects of steroid hormones
require at least hours to be e¡ective [50]. A recent
study suggested the existence of a cell surface recep-
tor for estrogen in the rat pituitary tumor cell and
also indicated that it may play a role in mediating
the non-genomic e¡ect [51]. In the vascular tissue,
17L-estradiol was suggested to induce vasorelaxation
by acting through the membrane receptor [52]. Fur-
thermore, a plasma membrane receptor for proges-
terone has been recently cloned in porcine vascular
smooth muscle cells [53]. However, whether or not
such membrane receptors contribute to the inhibition
of the Ca2 in£ux in endothelial cells or whether
steroid hormones directly bind to and modulate
Ca2 entry pathways still remains to be elucidated.
Estrogen replacement therapy in postmenopausal
women is reported to improve endothelium-depen-
dent relaxation and reduce the risk of heart disease
[6]. A combination of estrogen and progesterone is
recommended to postmenopausal women with an in-
tact uterus or those with an absence of familiar
breast cancer history. The e¡ect of the combined
therapy on the estrogen-induced improvement of en-
dothelium-dependent relaxation remains controver-
sial. In in vivo studies with human or experimental
animals, the improvement in endothelium-dependent
relaxation observed in the combined therapy regimen
was similar to that observed in the estrogen therapy
regimen [15,16], thus suggesting that addition of pro-
gesterone had no signi¢cant e¡ect on estrogen ther-
apy. On the other hand, in vitro studies with isolated
vascular tissues showed that progesterone antago-
nized the stimulatory e¡ects of estrogen on endothe-
lium-dependent response in canine coronary arteries
[13]. It was also reported that progesterone com-
pletely inhibited the estrogen-mediated improvement
of endothelium-dependent relaxation [14] or experi-
mental atherosclerosis [54]. The opposite e¡ects of
progesterone and 17L-estradiol on the Ca2 signaling
in endothelial cells as observed in the present study
may thus be linked to the reported antagonizing ef-
fects of progesterone on the estrogen-induced aug-
mentation of endothelium-dependent relaxation.
In conclusion, progesterone inhibited the [Ca2]i
elevations induced by thapsigargin and ET-1 in in
situ endothelial cells of the porcine aortic valve. We
consider that this e¡ect is due to the inhibition of the
Ca2 in£ux. On the other hand, 17L-estradiol rather
transiently augmented the responses to thapsigargin
and ET-1. Progesterone and estrogen are reported to
inhibit the voltage-operated Ca2 channels in smooth
muscle cells. Taking into account these observations,
we propose that progesterone is a wide-spectral in-
hibitor of the Ca2 in£ux, while estrogen is a rela-
tively speci¢c inhibitor of the voltage-operated Ca2
channels. The opposing e¡ects of progesterone and
estrogen on Ca2 signaling in endothelial cells may
be related to the antagonizing e¡ect of progesterone
on the estrogen-mediated enhancement of endothe-
lium-dependent relaxation observed in in vitro stud-
ies. These e¡ects of steroid hormones are considered
to be non-genomic e¡ects and therefore are not
mediated by cytosolic receptors.
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